Real-world efficacy, safety, and clinical outcomes of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin combination therapy in patients with hepatitis C virus genotype 1 or 4 infection: The Turkey experience experience

Background/Aims: mbitasvir/paritaprevir/ritonavir (OMV/PTV/r) ± dasabuvir (DSV) ± ribavirin (RBV) combination has demonstrated excellent rates of sustained virologic response (SVR) and a very good safety profile in patients with the chronic hepatitis C virus (HCV) genotype 1 or 4 infections. We aime...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Bilgehan Aygen, Neşe Demirtürk, Orhan Yıldız, Mustafa Kemal Çelen, İlhami Çelik, Şener Barut, Onur Ural, Ayşe Batırel, Reşit Mıstık, Funda Şimşek, Ali Asan, Gülden Ersöz, Nesrin Türker, Hüseyin Bilgin, Sami Kınıklı, Faruk Karakeçili, Gökmen Zararsız, The Study Group for Viral Hepatitis of the Turkish Society of Clinical Microbiology and Infectious Diseases*
Format:	Artigo
Jezik:	Inglês
Izdano:	Turkish Society of Gastroenterology 2020-04-01
Serija:	The Turkish Journal of Gastroenterology
Teme:	Chronic hepatitis C HCV genotypes 1 and 4 ombitasvir paritaprevir dasabuvir real-world effectiveness
Online dostop:	https://turkjgastroenterol.org/index.php/tjg/article/view/3574
Oznake:	Označite Brez oznak, prvi označite!